Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Danaher Corp.
DHRHealthcareGenerated Jul 5, 2026, 08:10 PM UTC
DHR (Danaher Corp.) analytical snapshot. Return on equity 9.62%, ROA 5.64%, ROIC 7.94%. Net income down ▼ +33.9% YoY. Debt/equity 0.35, current ratio 1.87, net debt $12.80B. Market cap $140.09B at $197.93 per share. Trailing P/E 31.02, P/S 8.30, P/B 2.65. EV/Operating income ≈ 29.39 (EV $152.89B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score -11 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$140.09B
707.77M shares
Price
$197.93
NYQ
P/E (ttm)
31.02
Revenue (FY)
—
Net margin
—
Free cash flow
$5.78B
Risk level
Low
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 5Stable
80% conf
Return on equity 9.62%, ROA 5.64%, ROIC 7.94%. Net income down ▼ +33.9% YoY. Debt/equity 0.35, current ratio 1.87, net debt $12.80B.
- Return on equity 9.62%, ROA 5.64%, ROIC 7.94%.
- Net income down ▼ +33.9% YoY.
- Debt/equity 0.35, current ratio 1.87, net debt $12.80B.
Revenue (FY)
—
Net margin
—
ROE
9.62%
ROA 5.64%
ROIC
7.94%
EPS (diluted)
$6.38
FY2025
Free cash flow
$5.78B
Debt / equity
0.35
Cash $5.69B
Current ratio
1.87
Equity $52.95B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $3.29B | 10.97 |
| 2017 | — | — | — | — | — | $3.29B | 14.60 |
| 2018 | $16.88B | — | 55.29 | 16.20 | 15.13 | $2.93B | 9.69 |
| 2019 | — | — | — | — | — | $2.91B | 8.83 |
| 2020 | — | — | — | — | — | $3.44B | 8.76 |
| 2021 | — | — | — | — | — | $3.32B | 7.56 |
| 2022 | — | — | — | — | — | $5.42B | 8.07 |
| 2023 | — | — | — | — | — | $7.12B | 12.84 |
| 2024 | — | — | — | — | — | $7.40B | 13.48 |
| 2025 | — | — | — | — | — | $5.78B | 9.62 |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 16,882
2019: 0
2020: 0
2021: 0
2022: 0
2023: 0
2024: 0
2025: 0
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 3,293
2017: 3,289
2018: 2,932
2019: 2,907
2020: 3,438
2021: 3,316
2022: 5,417
2023: 7,118
2024: 7,401
2025: 5,781
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 20Improving
80% conf
Latest annual report (10-K) filed Feb 24, 2026. Latest quarterly report (10-Q) filed Apr 21, 2026. 10 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 24, 2026.
- Latest quarterly report (10-Q) filed Apr 21, 2026.
- 10 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Danaher Corp.; broad institutional reporting.
- Recent filers include Aldebaran Financial Inc., INVESTORS TRUST CO /PA, Gardiner Nancy B.
Latest 10-K
Feb 24, 2026
Annual report
Latest 10-Q
Apr 21, 2026
8-K (recent)
10
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| Aldebaran Financial Inc. | 13F-HR | Aug 14, 2015 |
| INVESTORS TRUST CO /PA | 13F-HR | Feb 15, 2002 |
| Gardiner Nancy B | 13F-HR | Jul 26, 2017 |
| Fayerweather Charles | 13F-HR | Oct 26, 2017 |
| Gardiner Nancy B | 13F-HR | May 16, 2017 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 3, 2026 | 8-K | 8-K |
| May 7, 2026 | 8-K | 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Apr 21, 2026 | 8-K | 8-K |
| Apr 17, 2026 | 8-K | 8-K |
| Feb 17, 2026 | 8-K | 8-K |
| Feb 10, 2026 | 8-K | 8-K |
| Jan 28, 2026 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -62Deteriorating
72% conf
4 risk signal(s), 2 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
- Free cash flow deteriorating: FCF declined +21.9% YoY (from $7.40B to $5.78B). With OCF at $7.16B and capex at $1.38B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Operating cash flow exceeds net income: OCF is 1.50x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Deferred revenue growing — future revenue visibility: Deferred revenue grew +33.1% to $1.61B, providing forward revenue visibility. This is a positive leading indicator for subscription or contract-based businesses.
- Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
- Endogenous analysis: Strong cash conversion (OCF > NI) combined with growing deferred revenue provides high forward visibility. The business model appears to generate sustainable, recurring cash flows — a positive structural indicator.
- Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$16.88B
— YoY
Gross profit
$14.03B
-13.3% YoY
Operating income
$5.20B
-31.0% YoY
Net income
$4.76B
-33.9% YoY
Operating cash flow
$7.16B
-15.9% YoY
Capex
$1.38B
+23.7% YoY
Total assets
$84.49B
+0.2% YoY
Total liabilities
$7.68B
— YoY
Filing quality score
70/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | — | $16.88B | — | — |
| Gross profit | $16.19B | $14.03B | $-2.15B | -13.3% |
| Operating income | $7.54B | $5.20B | $-2.33B | -31.0% |
| Net income | $7.21B | $4.76B | $-2.44B | -33.9% |
| Operating cash flow | $8.52B | $7.16B | $-1.35B | -15.9% |
| Capex | $1.12B | $1.38B | $265.0M | +23.7% |
| Total assets | $84.35B | $84.49B | $138.0M | +0.2% |
| Total liabilities | — | $7.68B | — | — |
| Long-term debt | $18.40B | $16.00B | $-2.40B | -13.0% |
| Cash & equivalents | $790.8M | $963.7M | $172.9M | +21.9% |
| Stockholders equity | $53.49B | $49.54B | $-3.94B | -7.4% |
| Inventory | $2.59B | $2.33B | $-264.0M | -10.2% |
| Accounts receivable | $3.92B | $3.54B | $-385.0M | -9.8% |
| R&D expense | $1.53B | $1.50B | $-25.0M | -1.6% |
| SG&A expense | $7.12B | $7.33B | $205.0M | +2.9% |
| Interest expense | $275.0M | $231.0M | $-44.0M | -16.0% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccrualForEnvironmentalLossContingencies, AccruedEnvironmentalLossContingenciesNoncurrent, AccruedIncomeTaxesCurrent, AccruedIncomeTaxesNoncurrent, BusinessAcquisitionProFormaEarningsPerShareDiluted, BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareDiluted, BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax, BusinessAcquisitionsProFormaNetIncomeLoss, BusinessAcquisitionsProFormaRevenue, CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 3 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Restatement of financial statements | high | 2 | 0 | NEW |
| Impairment charge | medium | 40 | 5 | Ongoing |
| Restructuring | medium | 122 | 7 | Ongoing |
| Off-balance sheet arrangements | medium | 28 | 0 | NEW |
| Related party transactions | low | 7 | 0 | NEW |
Filing signal breakdown
Red flags: 4
Positive: 2
Watch: 2
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $140.09B at $197.93 per share.
- ProPrice & TechnicalsPrice $197.93 — downtrend (below 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Low.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -11
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Danaher Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewLatest annual report (10-K) filed Feb 24, 2026..
Risk
Low
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow DHR stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR● you | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |